PT. RICHMOND, Calif., Oct. 8 /PRNewswire/ -- Transcept Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company, announced today that Thomas P. Soloway, Senior Vice President and Chief Financial Officer, is scheduled to present at the Natixis Bleichroeder Second Annual Hidden Gems Conference in New York City on Monday, October 13, 2008 at 9:30 AM Eastern Time.
An audio webcast of the presentation will be available at http://www.wsw.com/webcast/nblr2/transcept/ and on the Transcept website at http://www.transcept.com. The replay of the presentation will be available for 30 days.
About Transcept Pharmaceuticals
Transcept Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the fields of psychiatry and sleep medicine. The lead Transcept product candidate, Intermezzo(R), is a sublingual low dose formulation of zolpidem that has been developed for use as-needed for the treatment of insomnia when a middle of the night awakening is followed by difficulty returning to sleep. Phase 3 clinical trials have been completed for Intermezzo(R) and, on September 30, 2008, Transcept submitted a New Drug Application to the U.S. Food and Drug Administration. For further information, please visit the company's website at: http://www.transcept.com.
This press release contains forward-looking statements for purposes of
the Private Securities Litigation Reform Act of 1995 (the "Act"). Transcept
disclaims any intent or obligation to update these forward-looking
statements, and claim the protection of the Safe Harbor for forward-looking
statements contained in the Act. Examples of such statements include, but
are not limited to, the expected benefits of Transcept product candidates.
Such statements are based on management's current expectations, but actual
results may differ materially due to various risks and uncertainties,
including, but not limited to, Transcept product candidates may have
unexpected adverse side effects or inadequate therapeutic efficacy;
positive results in clinical trials may not be sufficient to obtain FDA
approval; physician or patient reluctance to use Intermezzo(R), if
approved; potential alternative therapies; maintaining adequate patent or
trade secret protection without violating the intellectual property rights
of others; and other difficulties or delays in, clinical development,
obtaining regulatory approval, market acceptance and commercialization of
Transcept product candidates.
Transcept Pharmaceuticals, Inc.
Director of Communications
The Ruth Group
Investors / Media
Stephanie Carrington / Jason Rando
(646) 536-7017 / 7025
|SOURCE Transcept Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved